Deborah K. Armstrong, MD
Assoc. Professor
Johns Hopkins Kimmel Cancer Center
Medical Oncology
1650 Orleans St
Rm 190
Baltimore,
MD
USA
21287
Biographical Sketch: Dr. Deborah K. Armstrong is an Associate Professor of Oncology and of Gynecology & Obstetrics at Johns Hopkins in Baltimore, MD. Dr. Armstrong works primarily in the area of women’s malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. Dr. Armstrong’s clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are targeted biologic therapy, intraperitoneal therapy, and immunologic approaches to cancer treatment. Dr. Armstrong also directs the Johns Hopkins Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examining new strategies for cancer screening and prevention. Dr. Armstrong is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees. She is a member of the Oncology Drugs Advisory Committee for the US FDA."
Papers:
51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study
103
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact?
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian